Previous close | 0.8460 |
Open | 0.8290 |
Bid | 0.7704 x 100 |
Ask | 0.8594 x 100 |
Day's range | 0.7900 - 0.8500 |
52-week range | 0.5390 - 1.3400 |
Volume | |
Avg. volume | 402,233 |
Market cap | 61.299M |
Beta (5Y monthly) | 2.34 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s first quarter 2024 financial results on Tuesday, May 7, 2024, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical comp
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col (Ret.), FAASLD, who served as a trusted advisor and the Principal Investigator for the Company’s ongoing Phase 2a HERALD study in metabolic dysfunction